Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study

Clinical Therapeutics

Volumn 27, Issue 10, 2005, Pages 1548-1561

  Bailey, Clifford J ^a   Bagdonas, Alfredas ^b   Rubes, Josip ^c   McMorn, Stephen O ^d   Donaldson, Jill ^e   Biswas, Nandita ^d   Stewart, Murray W ^e  

^a ASTON UNIVERSITY   (United Kingdom)

^b Dainavos Family Medicine Center   (Lithuania)

^c Centar Za Diabetes   (Croatia)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Glycemic control; Metformin; Randomized controlled trial; Rosiglitazone; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE CHOLECYSTITIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY TRACT DISEASE; BODY MASS; CELL FUNCTION; CHOLELITHIASIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; INSULIN SENSITIVITY; IRRITABLE COLON; LIVER TOXICITY; LUNG EDEMA; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE JAUNDICE; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 28444440888     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.10.012     Document Type: Article

References (55)

1. Grant P.J., and Davies J.A. Cardiovascular diseases and diabetes Pickup J.C. Williams G. Textbook of Diabetes 3rd ed. 2003 Blackwell Sciences Ltd Oxford, UK 56.1 56.24
2. Stratton I.M., Adler A.I., and Neil H.A. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study BMJ 321 2000 405 412
3. American Diabetes Association Standards of medical care in diabetes Diabetes Care 27 Suppl 1 2004 S15 S35
4. American Association of Clinical Endocrinologists Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management - 2002 update Endocr Pract 8 2002 40 82
5. European Diabetes Policy Group 1999 A desktop guide to type 2 diabetes mellitus Diabet Med 16 1999 716 730
6. Canadian Diabetes Association Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada Can J Diabetes 27 Suppl 2 2003 i viii
7. Canadian Diabetes Association Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada Can J Diabetes 27 Suppl 2 2003 S1 S140
8. Latinamerican Diabetes Association (ALAD) Guidelines for the diagnosis, control and treatment of type 2 diabetes mellitus Revista De La Asociacion Latinoamericana De Diabetes 8 2000 101 167
9. on behalf of the Asian-Pacific Type 2 Diabetes Policy Group and IDF Western Pacific Region Asian-Pacific Type 2 Diabetes Policy Group Type 2 Diabetes: Practical Targets and Treatments Third Edition 2002 Health Communications Australia Pty Limited and In Vivo Communications Pty Limited Sydney, Australia
10. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes JAMA 291 2004 335 342
11. Liebl A., Mata M., Eschwege E., and ODE-2 Advisory Board Evaluation of risk factors for develop ment of complications in type II diabetes in Europe Diabetologia 45 2002 S23 S28
12. [published correction appears in Lancet. 1998;352:1557] UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with met formin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
13. [published correction appears in Diabetes. 1996;45:1655] UK Prospective Diabetes Study Group^ UK Prospective Diabetes Study 16. Overview of 6 years' ther apy of type II diabetes: A progressive disease Diabetes 44 1995 1249 1258
14. Campbell I.W. Need for intensive, early glycaemic control in patients with type 2 diabetes Br j Cardiol 7 2000 625 631
15. Brown J.B., Nichols G.A., and Perry A. The burden of treatment failure in type 2 diabetes Diabetes Care 27 2004 1535 1540
16. Bailey C.J., and Turner R.C. Drug therapy: Metformin N Engl J Med 334 1996 574 579
17. DeFronzo R.A., Goodman A.M. Multicenter Metformin Study Group Efficacy of metformin in pa tients with non-insulin-dependentdiabetes mellitus N Engl J Med 333 1995 541 549
18. Garber A.J., Duncan T.G., and Goodman A.M. Efficacy of metformin in type II diabetes: Results of a double blind, placebo-controlled, closeresponse trial Am J Med 103 1997 491 497
19. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 131 1999 281 303
20. Grant P.J. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in pa tients with type II diabetes Diabetes Care 19 1996 64 66
21. Grant P.J. The effects of metformin on cardiovascular risk factors Diabetes Metab Rev 11 Suppl 1 1995 S43 S50
22. McIntyre H.D., Ma A., and Bird D.M. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus Aust N Z J Med 21 1991 714 719
23. Stratton I., and Holman R. Is the cardioprotective effect of metformin in type 2 diabetes dose dependent? Diabetes 52 2003 A167 A168
24. [published corrections appear in J Clin Endocrinol Metab. 2001;86:1659 and J Clin Endocrinol Metab. 2002;2:iv] Lebovitz H.E., Dole J.F., Patwardhan R. Rosiglitazone Clinical Trials Study Group Rosiglitazone monotherapy is effective in patients with type 2 diabetes J Clin Endocrinol Metab 86 2001 280 288
25. St John Sutton M., Rendell M., and Dandona P. A comparison of the effects of rosiglitazone and gly buride on cardiovascular function and glycemic control in patients with type 2 diabetes Diabetes Care 25 2002 2058 2064
26. Haffner S.M., Greenberg A.S., and Weston W.M. Effect of rosiglitazone treatment on nontraditional mark ers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 106 2002 679 684
27. Wolffenbuttel B.H., Gomis R., and Squatrito S. Addition of lowdose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients Diabet Med 17 2000 40 47
28. [published correction appears in JAMA. 2000;284:1384] Fonseca V., Rosenstock J., Patwardhan R., and Salzman A. Effect of metformin and rosiglitazone combination ther apy in patients with type 2 diabetes mellitus: A randomized controlled trial JAMA 283 2000 1695 1702
29. Jones T.A., Sautter M., Van Gaal L.F., and Jones N.P. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes Diabetes Obes Metab 5 2003 163 170
30. Dailey G.E. III, Noor M.A., and Park J.S. Glycemic control with glyburide/ metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blindtrial Am J Med 116 2004 223 229
31. Roy R., Navar M., Palomeno G., and Davidson M.B. Real world effectiveness of rosiglitazone added to maxi mal (tolerated) doses of metformin and a sulfonylurea agent: A systematic evaluation oftriple oral therapy in a minority population Diabetes Care 27 2004 1741 1742
32. World Health Organization Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part I: Diagnosis and Classification of Diabetes Mellitus 1999 WHO Department of Noncommunicable Disease Surveillance Geneva, Switzerland
33. Matthews D.R., Hosker J.P., and Rudenski A.S. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
34. Bradley C. Diabetes Treatment Satisfaction Questionnaire (DTSQ) Bradley C. Handbook of Psychology and Diabetes: A Guide to Psychological Measurements in Diabetes Research and Management 1994 Harwood Academic Publishers Langhorne, Pa
35. Shaw M., Talley N.J., and Adlis S. Development of a digestive health status instrument: Tests of scaling assumptions, structure and reliability in a primary care population Aliment Pharmacol Ther 12 1998 1067 1078
36. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
37. Neter J., Wasserman W., and Kutner M.H. Applied Linear Statistical Methods 3rd ed. 1990 Irwin Boston, Mass
38. Hosmer D.W., and Lemeshow S. Applied Logistic Regression 1989 Wiley Interscience New York, NY
39. Bailey C.J., and Day C. Avandamet: Combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes Int J Clin Pract 58 2004 867 876
40. Inzucchi S.E., Maggs D.G., and Spollett G.R. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus N Engl J Med 338 1998 867 872
41. Miyazaki Y., Glass L., and Triplitt C. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients Diabetologia 44 2001 2210 2219
42. Stumvoll M., Nurjhan N., and Perriello G. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus N Engl J Med 333 1995 550 554
43. Buchanan T.A., Xiang A.H., and Peters R.K. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-riskHispanic women Diabetes 51 2002 2796 2803
44. Fridlyand L.E., and Philipson L.H. Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells? Diabetes 53 2004 1942 1948
45. Ritzel R.A., Hansen J.B., Veldhuis J.D., and Butler P.C. Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP) channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose J Clin Endocrinol Metab 89 2004 795 805
46. Viberti G.C. Rosiglitazone: Potential beneficial impact on cardiovascular disease Int J Clin Pract 57 2003 128 134
47. Ridker P.M., Rifai N., and Rose L. Comparison of C-reactive protein and low-density lipoprotein choles terol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
48. Weissman P., Goldstein B., and Campbell J. Rosiglitazone plus metformin combination effects on CV risk markers suggest potential CV benefits in type 2 diabetic patients Diabetes 53 2004 A28
49. Nesto R.W., Bell D., and Bonow R.O. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 27 2004 256 263
50. Donnan P.T., MacDonald T.M., and Morris A.D. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: A retrospective cohort study Diabet Med 19 2002 279 284
51. Lydick E., Gaskin M., and Bakst A.W. Discontinuation after start of oral hypoglycemic agents (OHA) in first year Diabetes 47 1998 A387
52. Vanderpoel D.R., Hussein M.A., Watson-Heidari T., and Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: A retrospectivedatabase analysis Clin Ther 26 2004 2066 2075
53. Home P., and Gubb J. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD): A long-term cardiovascular outcome study Diabetes 51 2002 A487
54. Beck-Nielson H., Hanefeld M., and Komajda M. Randomized controlled trial of the effect of rosiglita zone in combination therapy on ambulatory blood pressure in people with type 2 diabetes mellitus followed for 12 months Diabetologia 48 2005 A279
55. Home P.D., Pocock S., and Beck-Nielsen H. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): An interim analysis of glycaemia at 18 months Diabetologia 47 2004 A262